(0.26%) 5 145.00 points
(0.14%) 38 496 points
(0.42%) 17 922 points
(-0.64%) $83.31
(2.03%) $1.962
(-0.18%) $2 342.90
(-0.08%) $27.51
(2.83%) $948.20
(-0.05%) $0.934
(-0.09%) $11.01
(-0.27%) $0.798
(1.88%) $93.60
@ $3.11
発行日: 15 2月 2024 @ 03:43
リターン: -15.43%
前回のシグナル: 2月 15 - 01:27
前回のシグナル:
リターン: 3.15 %
Live Chart Being Loaded With Signals
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology...
Stats | |
---|---|
本日の出来高 | 260 297 |
平均出来高 | 1.54M |
時価総額 | 97.40M |
EPS | $0 ( 2024-03-12 ) |
次の収益日 | ( $-0.730 ) 2024-06-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.430 |
ATR14 | $0.00600 (0.23%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-15 | O'neill Vincent | Sell | 2 250 | Restricted Stock Units |
2024-03-15 | O'neill Vincent | Buy | 2 250 | Common Stock |
2024-04-04 | O'neill Vincent | Sell | 165 | Common Stock |
2024-03-14 | O'neill Vincent | Sell | 521 | Restricted Stock Units |
2024-03-14 | O'neill Vincent | Buy | 521 | Common Stock |
INSIDER POWER |
---|
-8.71 |
Last 87 transactions |
Buy: 187 774 | Sell: 228 648 |
ボリューム 相関
BioXcel Therapeutics Inc 相関
10 最も負の相関 | |
---|---|
CRSA | -0.937 |
LONE | -0.906 |
PPBT | -0.903 |
SNCR | -0.902 |
TSLA | -0.897 |
MVBF | -0.882 |
TLMD | -0.88 |
EPZM | -0.878 |
RMRM | -0.876 |
MTEK | -0.876 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
BioXcel Therapeutics Inc 相関 - 通貨/商品
BioXcel Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $1.38M |
総利益: | $-198 000 (-14.35 %) |
EPS: | $-6.15 |
FY | 2023 |
収益: | $1.38M |
総利益: | $-198 000 (-14.35 %) |
EPS: | $-6.15 |
FY | 2022 |
収益: | $375 000 |
総利益: | $355 000 (94.67 %) |
EPS: | $-6.13 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $0 |
Financial Reports:
No articles found.
BioXcel Therapeutics Inc
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。